Status:

COMPLETED

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

Lead Sponsor:

Amgen

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-R...

Detailed Description

Study with completed results acquired from Horizon in 2024.

Eligibility Criteria

Inclusion

  • Documented history of RA in agreement with ACR criteria
  • DMARD treatment for RA greater than or equal to 6 months, with a stable dose greater than or equal to 6 weeks prior to screening visit
  • Duration of morning stiffness greater than or equal to 45 minutes
  • greater than or equal to 4 swollen joints (out of 28)
  • greater than or equal to 4 tender joints (out of 28)

Exclusion

  • Suffering from another disease, which requires glucocorticoid treatment during the study period
  • Synovectomy within 4 months prior to study start
  • Use of glucocorticoids:
  • Continued use of systemic glucocorticoids within 4 weeks prior to screening visit
  • Intermittent use of glucocorticoids within 2 weeks prior to screening visit.
  • Joint injections within 6 weeks prior to screening visit
  • Topical glucocorticoids must be stopped at screening visit
  • Use of biologicals such as: tumor necrosis factor α (TNFα) inhibitors and other compounds within 5 serum half lives prior to screening visit
  • Pregnancy or nursing

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2009

Estimated Enrollment :

350 Patients enrolled

Trial Details

Trial ID

NCT00650078

Start Date

March 1 2008

End Date

May 1 2009

Last Update

December 18 2024

Active Locations (52)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (52 locations)

1

Rheumatology Associates of N. AL, P.C.

Huntsville, Alabama, United States, 35801

2

ArthoCare, Arthritis Care & Research, P.C.

Phoenix, Arizona, United States, 85012

3

The National Institute of Clinical Research

Los Angeles, California, United States, 90057

4

University of California, Los Angeles

Los Angeles, California, United States, 90095